Financing ·
SRX Global Inc. entered into a Securities Purchase Agreement on August 27, 2026, selling 3,579 shares of Series C…
SRXHSRX Global Inc.
SRX Global Inc. entered into a Securities Purchase Agreement on August 27, 2026, selling 3,579 shares of Series C convertible preferred stock to accredited investors for $2,862,500. The purchase price was satisfied by the assignment of Convertible Grid Promissory Notes from CERO Therapeutics Holdings with an aggregate principal amount of $2,812,500. Each share has a stated value of $1,000 and converts at a fixed price of $2.1888 per share into common stock. The company also entered a Registration Rights Agreement to register the resale of shares issuable upon conversion and warrant exercise. SRX Global Inc. operates in the biotechnology sector.